EU antitrust regulators to investigate Illumina, Grail deal By Reuters


© Reuters. FILE PHOTO: The offices of gene sequencing company Illumina Inc are shown in San Diego, California January 11, 2016. REUTERS/Mike Blake

BRUSSELS (Reuters) – EU antitrust regulators opened on Thursday a full-scale investigation into U.S. life sciences company Illumina Inc (NASDAQ:)’s proposed buy of cancer test maker Grail Inc, worried that the deal may curb innovation and competition.

The European Commission’s announcement confirmed a Reuters story last week.

“The proposed acquisition may reduce competition and innovation in the emerging market for the development and commercialisation of cancer detection tests based on sequencing technologies,” the EU executive, which acts as the competition enforcer for the 27-country bloc, said.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.